$Minerva Neurosciences(NERV.US)$ Roluperidone NDA receives CRL from FDA 🙁 ⚠️ FDA cited clinical deficiencies: ▪️ Insufficient substantial evidence of effectiveness ▪️ lacks data on concomitant antipsychotic admin. ▪️ lacks data to establish change in negative symptoms of schizophrenia ▪️ inadequate number of subjects exposed at proposed dose ℹ️Add'l info on Roluperidone… ⇒ for negative symptoms of schizophrenia ⇒ NDA ⇒ PDUFA: 02/26/24
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks. Here are some top stocks in the sector climbing on drug trial and earnings news: $Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap. $Ligand Pharmaceuticals (LGND.US)$gained 23%...
$Minerva Neurosciences(NERV.US)$If you have SL set? Pray they get hit. Ive seen way to many times when halt comes off it can drop so fast and hard, it will blow passed them by 30+%
Trytosaveabit楼主MangoXXXX:
Don’t know about fast! But yes if you like this for a swing trade and it gets the drop I expect? Would be a good place to start scaling in! I say scale in just in case it settles a bit more after drop? GL and big profits to ya
Minerva Neurosciences股票讨论区
$讯鸟软件(IFBD.US)$ $旭日升科技(ASTI.US)$ $Rail Vision(RVSN.US)$ $即亮集团(JL.US)$ $Minerva Neurosciences(NERV.US)$
📊⚡️📊
Roluperidone NDA receives CRL from FDA 🙁
⚠️ FDA cited clinical deficiencies:
▪️ Insufficient substantial evidence of effectiveness
▪️ lacks data on concomitant antipsychotic admin.
▪️ lacks data to establish change in negative symptoms of schizophrenia
▪️ inadequate number of subjects exposed at proposed dose
ℹ️Add'l info on Roluperidone…
⇒ for negative symptoms of schizophrenia
⇒ NDA
⇒ PDUFA: 02/26/24
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
暂无评论